Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis - Report - MDSpire

Comprehensive Immunophenotyping Identifies Unique Immune Profiles in Axial Spondyloarthritis and Psoriatic Arthritis

  • By

  • Natalie Frede

  • Nils Craig-Müller

  • Silke Kohrt

  • Marei-Theresa Bott

  • Ulrich Salzer

  • Ana Cecilia Venhoff

  • Jens Thiel

  • Julia Frede

  • Reinhard E. Voll

  • Marta Rizzi

  • Raquel Lorenzetti

  • Nils Venhoff

  • July 6, 2026

Share

Clinical Report: Comprehensive Immunophenotyping Identifies Unique Immune Profiles

Overview

This study reveals distinct immune profiles in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).

Background

Axial spondyloarthritis and psoriatic arthritis are immune-mediated inflammatory disorders that present significant clinical variability. Accurate diagnosis and treatment strategies remain challenging due to overlapping symptoms and disease mechanisms.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Distinct immune signatures were identified in patients with axSpA compared to those with PsA.
  • Single-omics methodologies have limitations in capturing the multifaceted nature of axSpA and PsA.
  • Early differential diagnosis remains a significant clinical challenge.

Clinical Implications

Clinicians should consider the unique immune profiles when evaluating patients.

Conclusion

Further research is warranted to explore the clinical applications of these findings.

Related Resources & Content

  1. Frede N., et al., Frontiers in Immunology, 2026 -- Comprehensive Immunophenotyping Identifies Unique Immune Profiles in Axial Spondyloarthritis and Psoriatic Arthritis
  2. Frontiers in Medicine — Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies
  3. npj Digital Medicine — Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets
  4. Frontiers in Medicine — Cross-disease immune cells atlas reveals the similarities and differences of cell characteristics and interactions in rheumatic diseases
  5. https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt424f1e71604af245/axspa-guideline-summary-2026.pdf
  6. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update - PMC
  7. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies - PubMed
  8. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study | Annals of the Rheumatic Diseases
  9. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study - PubMed
  10. Immune response and cytokine pathways in psoriatic arthritis: A systematic review - PMC

Original Source(s)

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

  • by Natalie Frede, Nils Craig-Müller, Silke Kohrt, Marei-Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff

  • July 6, 2026

Related Content

Efficacy Comparison of Cycling Versus Transitioning to IL-17 Inhibitors Following Initial TNF Inhibitor Failure in Psoriatic Arthritis: A Multicenter Real-World Analysis

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs